- Home
- OBIO vs MGNX Comparison
OBIO vs MGNX Comparison
Compare OBIO & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- MGNX
- Stock Information
- Founded
- OBIO 2017
- MGNX 2000
- Country
- OBIO United States
- MGNX United States
- Employees
- OBIO N/A
- MGNX N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- OBIO Health Care
- MGNX Health Care
- Exchange
- OBIO Nasdaq
- MGNX Nasdaq
- Market Cap
- OBIO 118.8M
- MGNX 114.2M
- IPO Year
- OBIO N/A
- MGNX 2013
- Fundamental
- Price
- OBIO $3.29
- MGNX $1.71
- Analyst Decision
- OBIO Strong Buy
- MGNX Hold
- Analyst Count
- OBIO 5
- MGNX 9
- Target Price
- OBIO $14.20
- MGNX $5.33
- AVG Volume (30 Days)
- OBIO 303.1K
- MGNX 1.2M
- Earning Date
- OBIO 08-11-2025
- MGNX 08-05-2025
- Dividend Yield
- OBIO N/A
- MGNX N/A
- EPS Growth
- OBIO N/A
- MGNX N/A
- EPS
- OBIO N/A
- MGNX N/A
- Revenue
- OBIO $2,886,000.00
- MGNX $154,050,000.00
- Revenue This Year
- OBIO $20.47
- MGNX N/A
- Revenue Next Year
- OBIO $11.45
- MGNX N/A
- P/E Ratio
- OBIO N/A
- MGNX N/A
- Revenue Growth
- OBIO 30.23
- MGNX 255.31
- 52 Week Low
- OBIO $2.37
- MGNX $0.99
- 52 Week High
- OBIO $8.30
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- OBIO 60.31
- MGNX 59.62
- Support Level
- OBIO $3.05
- MGNX $1.47
- Resistance Level
- OBIO $3.24
- MGNX $1.88
- Average True Range (ATR)
- OBIO 0.16
- MGNX 0.12
- MACD
- OBIO 0.03
- MGNX 0.03
- Stochastic Oscillator
- OBIO 93.75
- MGNX 68.81
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.